{
    "clinical_study": {
        "@rank": "129703", 
        "brief_summary": {
            "textblock": "The goals of this study are:\n\n        1. To assess the safety of bivalirudin in infants under six months with arterial or venous\n           thrombosis;\n\n        2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as\n           measured by the activated clotting time (ACT) or activated partial thromboplastin time\n           (aPTT) in Infants Under Six Months with arterial or venous thrombosis;\n\n        3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution\n           and bleeding complications compared to patients on unfractionated heparin (UH) or low\n           molecular weight heparin (LMWH)."
        }, 
        "brief_title": "Study Of Angiomax In Infants Under Six Months With Thrombosis", 
        "completion_date": "December 2004", 
        "condition": "Thrombosis", 
        "condition_browse": {
            "mesh_term": "Thrombosis"
        }, 
        "detailed_description": {
            "textblock": "The goals of this study are:\n\n        1. To assess the safety of bivalirudin in infants under six months with arterial or venous\n           thrombosis;\n\n        2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as\n           measured by the activated clotting time (ACT) or activated partial thromboplastin time\n           (aPTT) in Infants Under Six Months with arterial or venous thrombosis;\n\n        3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution\n           and bleeding complications compared to patients on unfractionated heparin (UH) or low\n           molecular weight heparin (LMWH)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Parent/legal-guardian has provided written informed consent before initiation of any\n             study related procedures.\n\n          -  Objectively confirmed thrombotic event by either doppler ultrasound, echocardiogram,\n             CT scan, MRI, MR angiogram, MR venogram, venogram or arteriogram.\n\n          -  Age less than 6 months .\n\n          -  Gestational age greater than 35 weeks\n\n          -  Expected life expectancy at least 14 days.\n\n          -  No contraindication to anticoagulation i.e. bleeding complications.\n\n        Exclusion Criteria:\n\n          -  Active or recent (less than 7 days) bleeding.\n\n          -  Known allergy to Angiomax or hirudin, or known sensitivity to any component of the\n             product.\n\n          -  Participation in other clinical research studies involving the evaluation of other\n                investigational drugs or devices within 30 days of enrollment.\n\n          -  Refusal to undergo blood transfusion should it become necessary.\n\n          -  Any other disease or condition, which, in the judgment of the Investigator would\n             place a patient at undue risk by being enrolled in the trial.\n\n          -  Baseline prolonged PT (>18 secs) or aPTT (>55 secs)\n\n          -  Platelet  count < 50,000 cells/mm3\n\n          -  Birth Trauma\n\n          -  Planned or indicated surgery within 30 days\n\n          -  Major or minor bleeding event"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "August 7, 2002", 
        "id_info": {
            "nct_id": "NCT00043277", 
            "org_study_id": "TMC-BIV-02-04"
        }, 
        "intervention": {
            "intervention_name": "Angiomax (bivalirudin)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antithrombins", 
                "Bivalirudin"
            ]
        }, 
        "keyword": [
            "neonates", 
            "thrombosis", 
            "bivalirudin", 
            "direct thrombin inhibitor"
        ], 
        "lastchanged_date": "January 31, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "Orange", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92868"
                }, 
                "name": "Children's Hospital of Orange County"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Dose Finding And Efficacy Study Of Angiomax\u00ae (Bivalirudin) As Primary Anticoagulation In Infants Under Six Months With Thrombosis", 
        "overall_official": {
            "affiliation": "Children's Hospital Orange County", 
            "last_name": "Guy Young, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "Observation of improvement for thrombosis or by clinical exam such as: Decrease in size of thrombus, restoration of flow through an occluded vessel, decrease in diameter of extremity or head."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043277"
        }, 
        "secondary_outcome": {
            "measure": "In addition, efficacy will also be judged by demonstrating a decrease in the molecular markers of thrombin generation."
        }, 
        "source": "The Medicines Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Medicines Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2006"
    }, 
    "geocoordinates": {
        "Children's Hospital of Orange County": "33.788 -117.853"
    }
}